BioAge Labs vs ProJenX
BioAge Labs
We are harnessing the biology of human aging to develop novel targets and therapies for metabolic diseases
99 employees · est. 2015 · Emeryville, United States
ProJenX
ProJenX is a clinical-stage biotech developing novel, brain-penetrant MAP4K inhibitors for ALS & other diseases
9 employees · est. 2021 · New York, United States
BioAge Labs is the older company (2015 vs 2021); BioAge Labs is the larger of the two.
4 signals in the last 90 days
Side-by-Side Comparison
| Metric | BioAge Labs | ProJenX |
|---|---|---|
| Founded | ||
| Founded | 2015 older | 2021 |
| Headquarters | ||
| Headquarters | Emeryville, United States | New York, United States |
| Employees | ||
| Employees | 99 larger | 9 |
| Industry | ||
| Industry | Biopharma, Biotechnology, Health and Wellness | Biopharma, Biotechnology, Health Care |
| Funding Stage | ||
| Funding Stage | Series D | Series A |
| Total Funding | ||
| Total Funding | $293.90M | $21.00M |
| Funding Rounds | ||
| Funding Rounds | 4 | 3 |
| Services | ||
| Services | Development of therapies for metabolic diseases, Research on NLRP3 inhibitors, Development of APJ agonists for weight loss, Multi-omics data analysis for aging research | Drug Development for ALS, Clinical Trial Execution, Research and Development of Neurodegenerative Therapies, Discovery and Preclinical Testing of Kinase Inhibitors |
| Target Customers | ||
| Target Customers | Pharmaceutical companies, Biotech investors, Healthcare providers, Patients with metabolic diseases | Individuals with Amyotrophic Lateral Sclerosis (ALS), Healthcare Providers in Neurology, Research Institutions Focusing on Neuroscience, Neurodegenerative Disease Community |
| Taxonomy | ||
| Taxonomy | BiopharmaceuticalMetabolic DiseasesHuman Aging BiologyNLRP3 InhibitorCardiovascular RiskRetinal Diseases +8 | Clinical-stage BiotechnologyNeurodegenerative DiseasesALS TherapyBrain-penetrant TherapiesMAPK TherapeuticsMotor Neuron Degenerative Pathways +7 |
| Website | ||
| Website | bioagelabs.com | projenx.com |
About BioAge Labs
BioAge Labs, founded in 2015, stands at the forefront of the biopharmaceutical industry, leveraging the biology of human aging to devise novel therapeutic targets for metabolic diseases. Positioned in the United States, this clinical-stage company is actively developing therapeutic product candidate...
About ProJenX
ProJenX, founded in 2021, is a clinical-stage biotechnology company based in the United States. Specializing in targeted, brain-penetrant treatments for neurodegenerative diseases, it focuses initially on ALS with its lead therapy candidate, prosetin. Emerging from a collaboration with Project ALS...
Also comparing in this category
Comparing more than these two?
Get BioAge Labs, ProJenX and up to nine more competitors side by side in one PDF: team, funding, traffic and every dated move of the last six months. Every company is re-checked on the day you order.
How does BioAge Labs compare?
A PDF of BioAge Labs and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.
This takes a few seconds: we look beyond our own index too.
Frequently Asked Questions
Compare BioAge Labs with someone else
Start typing a company name or domain.
Compiled from the BounceWatch company index. We last looked at BioAge Labs on 9 Jun 2026, and ProJenX on 9 Jun 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.
